Research programme: psychedelic microneedle patch - PharmaTher
Latest Information Update: 10 Aug 2021
Price :
$50 *
At a glance
- Originator PharmaTher
- Class Analgesics; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurological disorders; Neuromuscular disorders; Pain; Psychiatric disorders
Most Recent Events
- 10 Jun 2021 PharmaTher plans a clinical development for psychedelic microneedle patch (for delivery of psychedelics) for Psychiatric disorders, Neurological disorders, Neuromuscular disorders and Pain in 2022 (Transdermal)
- 30 Apr 2021 Psychedelic microneedle patch - PharmaTher is available for licensing as of 27 Apr 2021.
- 23 Feb 2021 PharmaTher in-licenses gelatin methacryloyl based microneedle delivery technology from the University of California at Los Angeles before February 2021